<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00921245</url>
  </required_header>
  <id_info>
    <org_study_id>13027</org_study_id>
    <secondary_id>EX0710ZA</secondary_id>
    <nct_id>NCT00921245</nct_id>
  </id_info>
  <brief_title>FREEDOM - First Real-Life Evaluation of Enablex Done in ZA Overactive Bladder Patients During a 3 Months Period</brief_title>
  <acronym>FREEDOM</acronym>
  <official_title>First REal-life Evaluation of Darifenacin in Overactive Bladder Patients During 3 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patient perspective on Overactive Bladder and symptoms experienced after administration of
      Darifenacin
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate safety and tolerability of Darifenacin in the daily practice for the treatment of the OAB (Over Active Bladder) syndrome.</measure>
    <time_frame>3 months later</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the patient's perception of bladder condition, the patient's use of the patient support program, the patient's and physician's assessment of treatment regarding efficacy and tolerability and patient's compliance with the treatment</measure>
    <time_frame>3 months later</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">9</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darifenacin (Emselex, BAY79-4998)</intervention_name>
    <description>Patients in daily clinical treatment receiving Emselex according to local drug information</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Private Practice Patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients &gt; 18 years with symptoms of overactive bladder.

        Exclusion Criteria:

          -  Contraindications for the treatment with Darifenacin prolonged-release tablets
             according to the registered package insert.

          -  Pregnancy and lactation. Women of childbearing potential have to use an acceptable
             method of contraception.

          -  Concomitant treatment with drugs known to affect mainly the urinary bladder function
             (e.g. anticholinergics, antispasmodics) at any time during the study. Concomitant
             treatment with botulinum toxin, capsaicin or resiniferatoxin at any time during the
             study and treatment with botulinum toxin, capsaicin or resiniferatoxin in the last 6
             months prior to Visit 1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2009</study_first_submitted>
  <study_first_submitted_qc>June 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2009</study_first_posted>
  <last_update_submitted>April 17, 2015</last_update_submitted>
  <last_update_submitted_qc>April 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2015</last_update_posted>
  <responsible_party>
    <name_title>Medical Director</name_title>
    <organization>Bayer Healthcare AG</organization>
  </responsible_party>
  <keyword>Overactive Bladder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darifenacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

